TORONTO and HAIFA, Israel, Sept. 11, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a pioneering biopharmaceutical company developing exosome-based regenerative therapies, is pleased to provide the following corporate updates. Israeli Patent Grant Expands Global Jurisdiction The Israel Patent Office has granted the Company’s Patent, entitled “Production of Extracellular Vesicles from Stem Cells.” This grant aligns with NurExone’s recently ...